Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials

Background. Absent adaptive, individualized dose-finding in early-phase oncology trials, subsequent ‘confirmatory’ Phase III trials risk suboptimal dosing, with resulting loss of statistical power and reduced probability of technical success for the investigational therapy. While progress has been m...

Descripción completa

Detalles Bibliográficos
Autor principal: Norris, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473410/
https://www.ncbi.nlm.nih.gov/pubmed/28663782
http://dx.doi.org/10.12688/f1000research.10624.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473410/
https://www.ncbi.nlm.nih.gov/pubmed/28663782
http://dx.doi.org/10.12688/f1000research.10624.3

Ejemplares similares